AU2018250217B2 - ASK1 inhibitor compounds and uses thereof - Google Patents
ASK1 inhibitor compounds and uses thereof Download PDFInfo
- Publication number
- AU2018250217B2 AU2018250217B2 AU2018250217A AU2018250217A AU2018250217B2 AU 2018250217 B2 AU2018250217 B2 AU 2018250217B2 AU 2018250217 A AU2018250217 A AU 2018250217A AU 2018250217 A AU2018250217 A AU 2018250217A AU 2018250217 B2 AU2018250217 B2 AU 2018250217B2
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- group
- compound
- alkyl
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482085P | 2017-04-05 | 2017-04-05 | |
| US62/482,085 | 2017-04-05 | ||
| PCT/US2018/026134 WO2018187506A1 (en) | 2017-04-05 | 2018-04-04 | Ask1 inhibitor compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018250217A1 AU2018250217A1 (en) | 2019-11-07 |
| AU2018250217B2 true AU2018250217B2 (en) | 2022-05-19 |
Family
ID=63712299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018250217A Active AU2018250217B2 (en) | 2017-04-05 | 2018-04-04 | ASK1 inhibitor compounds and uses thereof |
Country Status (34)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3572401B1 (en) * | 2017-01-22 | 2021-09-29 | Fujian Cosunter Pharmaceutical Co., Ltd. | Ask1 inhibitor and preparation method and use thereof |
| PL3621615T3 (pl) | 2017-05-12 | 2024-03-25 | Enanta Pharmaceuticals, Inc. | Inhibitory regulujące sygnał apoptozy kinazy 1 i sposoby ich stosowania |
| US11434249B1 (en) | 2018-01-02 | 2022-09-06 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| WO2019213244A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10654833B2 (en) | 2018-06-28 | 2020-05-19 | Hepatikos Therapeutics, Llc | ASK1 isoindolin-1-one inhibitors and methods of use thereof |
| WO2020041417A1 (en) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020198214A1 (en) * | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN112409332B (zh) * | 2019-08-23 | 2023-12-08 | 广东东阳光药业股份有限公司 | 三氮唑衍生物及其在药物中的应用 |
| CN115605476B (zh) | 2019-12-27 | 2024-05-24 | 鲁宾有限公司 | 取代的三环化合物 |
| EP4143186A1 (en) | 2020-05-01 | 2023-03-08 | Pfizer Inc. | Azalactam compounds as hpk1 inhibitors |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| EP4188549A1 (en) * | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2024020458A1 (en) * | 2022-07-20 | 2024-01-25 | Seal Rock Therapeutics, Inc. | Method of treating organ diseases or disorders with ask1 inhibitors |
| WO2025233319A1 (en) | 2024-05-06 | 2025-11-13 | Genfit | (1,2,4-triazol-3-yl)-2-pyridyl-1-isoindolinone for use in the treatment of sepsis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214359A1 (en) * | 2016-06-10 | 2017-12-14 | Venenum Biodesign Llc | Novel clostridium difficile toxin inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| TWI491606B (zh) * | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| US8802695B2 (en) * | 2010-02-03 | 2014-08-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| WO2012079022A1 (en) * | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| JP5927201B2 (ja) * | 2010-12-16 | 2016-06-01 | カルチャン リミテッド | Ａｓｋ１阻害ピロロピリミジン誘導体 |
| WO2016049069A1 (en) * | 2014-09-24 | 2016-03-31 | Gilead Sciences, Inc. | Methods of treating liver disease |
| EP3572401B1 (en) * | 2017-01-22 | 2021-09-29 | Fujian Cosunter Pharmaceutical Co., Ltd. | Ask1 inhibitor and preparation method and use thereof |
| PL3572412T3 (pl) | 2017-01-22 | 2021-09-27 | Fujian Cosunter Pharmaceutical Co., Ltd. | Pochodna pirydyny jako inhibitor ask1 oraz sposób jej wytwarzania oraz zastosowanie |
| US11168095B2 (en) | 2017-02-07 | 2021-11-09 | Biogen Ma Inc. | ASK1 inhibiting agents |
| CN109071498B (zh) | 2017-02-16 | 2021-03-30 | 四川科伦博泰生物医药股份有限公司 | 激酶抑制剂及其制备方法和用途 |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| WO2018157277A1 (en) | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
| US11136324B2 (en) | 2017-03-03 | 2021-10-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors |
| WO2018183122A1 (en) | 2017-03-27 | 2018-10-04 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
| US20200308165A1 (en) * | 2017-09-13 | 2020-10-01 | D.E. Shaw Research, Llc | Compounds as Ras Inhibitors and Use Thereof |
| US10654833B2 (en) * | 2018-06-28 | 2020-05-19 | Hepatikos Therapeutics, Llc | ASK1 isoindolin-1-one inhibitors and methods of use thereof |
-
2017
- 2017-06-16 JO JOP/2019/0221A patent/JOP20190221A1/ar unknown
-
2018
- 2018-04-03 TW TW107111742A patent/TWI779022B/zh active
- 2018-04-04 CU CU2019000080A patent/CU20190080A7/es unknown
- 2018-04-04 ES ES18780760T patent/ES2992084T3/es active Active
- 2018-04-04 SI SI201831140T patent/SI3606519T1/sl unknown
- 2018-04-04 KR KR1020197032180A patent/KR102665145B1/ko active Active
- 2018-04-04 WO PCT/US2018/026134 patent/WO2018187506A1/en not_active Ceased
- 2018-04-04 CN CN201880037304.1A patent/CN110730661B/zh active Active
- 2018-04-04 SG SG11201909155V patent/SG11201909155VA/en unknown
- 2018-04-04 FI FIEP18780760.7T patent/FI3606519T3/fi active
- 2018-04-04 US US16/499,075 patent/US20210087167A1/en not_active Abandoned
- 2018-04-04 CR CR20190503A patent/CR20190503A/es unknown
- 2018-04-04 NZ NZ758345A patent/NZ758345A/en unknown
- 2018-04-04 PT PT187807607T patent/PT3606519T/pt unknown
- 2018-04-04 PE PE2019001990A patent/PE20200009A1/es unknown
- 2018-04-04 DK DK18780760.7T patent/DK3606519T3/da active
- 2018-04-04 AU AU2018250217A patent/AU2018250217B2/en active Active
- 2018-04-04 MA MA049047A patent/MA49047A/fr unknown
- 2018-04-04 HU HUE18780760A patent/HUE068103T2/hu unknown
- 2018-04-04 RU RU2019134679A patent/RU2019134679A/ru not_active Application Discontinuation
- 2018-04-04 JP JP2019553366A patent/JP7196093B2/ja active Active
- 2018-04-04 EA EA201992299A patent/EA201992299A1/ru unknown
- 2018-04-04 CA CA3059107A patent/CA3059107A1/en active Pending
- 2018-04-04 PL PL18780760.7T patent/PL3606519T3/pl unknown
- 2018-04-04 MX MX2019012013A patent/MX394098B/es unknown
- 2018-04-04 EP EP18780760.7A patent/EP3606519B1/en active Active
- 2018-04-05 AR ARP180100846A patent/AR111407A1/es active IP Right Grant
- 2018-05-03 US US15/970,587 patent/US10150755B2/en active Active
-
2019
- 2019-09-26 IL IL269711A patent/IL269711B/en unknown
- 2019-10-02 CL CL2019002810A patent/CL2019002810A1/es unknown
- 2019-10-03 NI NI201900102A patent/NI201900102A/es unknown
- 2019-10-03 PH PH12019502288A patent/PH12019502288A1/en unknown
- 2019-10-04 DO DO2019000255A patent/DOP2019000255A/es unknown
- 2019-10-23 CO CONC2019/0011708A patent/CO2019011708A2/es unknown
- 2019-10-31 EC ECSENADI201978393A patent/ECSP19078393A/es unknown
-
2024
- 2024-09-26 US US18/897,798 patent/US20250304552A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214359A1 (en) * | 2016-06-10 | 2017-12-14 | Venenum Biodesign Llc | Novel clostridium difficile toxin inhibitors |
Non-Patent Citations (4)
| Title |
|---|
| Banini et al. 'Current and future pharmacologic treatment of nonalcoholic steatohepatitis' Curr Opin Gastroenterol. 2017 May; 33(3): 134–141. * |
| CHIAKI YAMAMOTO ET AL, "Copper-Catalyzed Intramolecular Benzylic C-H Amination for the Synthesis of Isoindolinones", JOURNAL OF ORGANIC CHEMISTRY, US, (2016-08-18), vol. 81, no. 17, pages 7675 - 7684. doi:10.1021/acs.joc.6b01393 * |
| GUOLAN DOU ET AL, "Efficient and Convenient Synthesis of Indazol-3(2 H )-ones and 2-Aminobenzonitriles", JOURNAL OF COMBINATORIAL CHEMISTRY., US, (2009-11-09), vol. 11, no. 6, doi:10.1021/cc9001058, ISSN 1520-4766, pages 1073 - 1077 * |
| MARION LANIER ET AL, "Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure", ACS MEDICINAL CHEMISTRY LETTERS, US, (2017-02-08), vol. 8, no. 3, doi:10.1021/acsmedchemlett.6b00481, ISSN 1948-5875, pages 316 - 320 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018250217B2 (en) | ASK1 inhibitor compounds and uses thereof | |
| KR102797127B1 (ko) | 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도 | |
| CN108602776B (zh) | 用作irak抑制剂的杂芳基化合物及其用途 | |
| ES2660914T3 (es) | Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD | |
| JP6001048B2 (ja) | チアゾロピリミジン化合物 | |
| IL213277A (en) | A5ns inhibitors of jaundice virus c | |
| KR20170044204A (ko) | 오렉신―１ 수용체의 억제제로서의 치료 화합물 | |
| CA3066946A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| KR20180021820A (ko) | Ido 억제제 | |
| AU2021219097A1 (en) | P2X3 modulators | |
| AU2010234241A1 (en) | Inhibitors of HIV replication | |
| US12427146B2 (en) | C-terminal SRC kinase inhibitors | |
| CN103874697A (zh) | 二苯并氧杂*衍生物 | |
| JP7233130B2 (ja) | Ｉｒａｋ４阻害剤としての新規な三環式化合物 | |
| KR101368079B1 (ko) | Ｊｎｋ 의 억제제 | |
| WO2015181394A1 (en) | Novel il-2/il-15 receptor antagonist compounds and uses thereof for the treatment of autoimmune and inflammatory diseases or graft rejection | |
| TWI652265B (zh) | 氮雜吲哚衍生物 | |
| AU2021241502A1 (en) | Potent and selective irreversible inhibitors of IRAK1 | |
| EA040632B1 (ru) | Соединения, ингибирующие ask1, и их применение | |
| BR112019021021B1 (pt) | Compostos de inibidor de ask1, usos dos mesmos e composições farmacêuticas | |
| HK40013582B (en) | Ask1 inhibitor compounds and uses thereof | |
| HK40013582A (en) | Ask1 inhibitor compounds and uses thereof | |
| HK1207063B (en) | Aromatic amide derivative as well as preparation method and medicinal application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |